Novo Nordisk to Invest $4.1 Billion in New Facility to North Carolina

By Denny Jacob

Novo Nordisk plans to invest $4.1 billion to build a second fill and finishing manufacturing facility in Clayton, N.C., as demand for weight-loss drugs show no signs of letting up.

The Danish drug maker -- known for its weight-loss drugs Wegovy and Ozempic -- said the new plant would be its largest in the state, doubling the combined square footage of its three existing facilities.

Construction will gradually be finalized between 2027 and 2029, Novo said. It would add about 1,000 jobs, the company said.

Novo said it plans to invest about $6.8 billion in production this year, up from actual investments of $3.9 billion last year to increase supply.

The announced investment comes nearly a year after Novo found bacteria in batches of the main ingredient for a diabetes pill that is a cousin to the popular diabetes and weight-loss drugs and was made at a North Carolina plant in 2023.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

June 24, 2024 15:26 ET (19:26 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.